Compare Cytokinetics Inc (CYTK) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Cytokinetics Inc trades at $62.61 (market cap $8.62B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.74 (market cap $2.03B). The key difference: Cytokinetics Inc is far larger — about 4.2× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| CYTK | TMF | |
|---|---|---|
Market Cap | $8.62B | $2.03B |
Volume | 2,594,626 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $87.26 | $44.14 |
52-Week Low | $54.76 | $25.19 |
Typical Hold Time | 19 Days | 28 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.64 with a 1.61% daily gain amid elevated volume. Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators are neutral. The ETF saw increased trading activity with over 5.2 million shares changing hands, as reported by Defense World on October 3, 2026. A dividend of $0.35 is scheduled for payment on September 29, 2026.
The outlook for TMF remains tied to long-term Treasury bond performance, with current technical weakness suggesting near-term pressure. Investment opportunity exists for investors bullish on declining long-term interest rates, but risks include interest rate volatility and the leveraged nature of the ETF amplifying losses. Market sentiment appears mixed given conflicting technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
